603127 昭衍新药
2024/12 -
人民幣(K¥)

变动
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
2019/12
人民幣(K¥)
营业总收入2,018,334-15.07%2,267,9711,516,6801,075,905639,379
减:营业总成本1,763,7488.74%1,418,7661,086,978804,306455,637
    其中:营业成本1,444,5605.93%1,181,660777,558523,092306,314
               财务费用(99,773)-33.96%(154,682)(19,156)2,477(2,025)
               资产减值损失(66,540)113.05%(2,792)(1,331)(1,510)(3,965)
公允价值变动收益(127,049)-48.28%349,567157,77758,94610,330
投资收益36,012274.04%13,02217,0001,52413,228
    其中:对联营企业和合营企业的投资收益15,471-604.08%(2,691)(426)----
营业利润104,347-79.42%1,225,639642,889361,118215,713
利润总额104,039-79.48%1,240,002642,004360,572215,460
减:所得税费用34,284-70.29%166,80285,58746,94428,853
净利润69,755-82.19%1,073,200556,416313,628186,607
减:非控股权益(4,320)-20.58%(1,057)(1,043)(1,386)(161)
股东净利润74,075-81.34%1,074,257557,460315,014186,768

市场价值指针
每股收益 (元) *0.100-81.13%1.4401.0801.0000.830
每股派息 (元) *0.030-81.25%0.4000.3600.3500.340
每股净资产 (元) *10.779-2.36%15.27718.7205.3905.111
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容